Results of this meta-analysis highlight the potential advantages of long-acting injectable antipsychotics vs oral antipsychotics in treating schizophrenia.
As antipsychotic medications are vital to the effective management of severe psychiatric disorders, investigators sought to examine reasons for medication nonadherence in patients with schizophrenia, bipolar disorders, and other psychotic disorders.
In considering patients with schizophrenia for cognitive remediation, comorbid OCD must be taken into account.
Youth receiving antipsychotic treatment have adverse changes in adiposity and insulin sensitivity, with the greatest fat increases seen with olanzapine.
These results indicate that impaired visual integration in patients with schizophrenia may more broadly be a feature of psychosis, rather than specifically of schizophrenia.
Researchers hope that in demonstrating the potential efficacy of MIN-101, they may improve the pharmacotherapy options available to patients with schizophrenia.
A substantial proportion of these individuals diagnosed with HIV, psychiatric disorders, and substance use disorders are out of care and urgently require intervention.
The superior benefit provided by early intervention services for schizophrenia could be cost-effective, and the researchers call for widespread implementation and funding of early intervention services in the United States and globally.
Researchers conducted a systematic literature review to identify cohort studies reporting the standardized incidence ratio for the risk of breast cancer in women with schizophrenia compared with the general population.
Investigators examined the long-term efficacy of deutetrabenazine measured by Abnormal Involuntary Movement Scale, Clinical Global Impressions Scale, and Patients' Global Impression of Change Scale in real-word clinical practice settings.
Adjunctive raloxifene may reduce negative symptom scores in women with schizophrenia or schizoaffective disorder.
The phase 3 study assessed the antipsychotic efficacy and safety of ALKS 3831 in patients with acute exacerbations of schizophrenia.
These data may be helpful in titrating care for those with schizotypal disorder and comorbid substance abuse disorders to mitigate the risk for conversion to schizophrenia.
Concerns over Nuplazid were initially voiced in a CNN article in early April which reported that the drug had been associated with over 700 deaths since its launch in March 2017.
These findings may be helpful in developing treatment strategies for patients with past trauma and sleep disturbances to attenuate the possibility of future psychosis-like experiences.
Communities that favor consanguineous marriage should receive sensitive advice on the risks involved to aid in reproductive decision making.
The authors advised clinicians to carefully consider which antipsychotics they prescribe their patients with metabolic dysfunction, as some are known to be diabetogenic.
These data may be useful to clinicians in considering the risks and benefits of prescribing haloperidol for patients with cardiac morbidity.
In patients with a history of pre-diagnostic violence, a history of non-violent offending in the 18-month period pre-diagnosis was the strongest predictor of future violence.
Major depressive disorder with psychotic features had comparative long-term outcomes with schizophrenia, schizoaffective disorder, and bipolar disorder.
The authors pointed to a possible difference in the specific symptoms alleviated by different types of stimulation.
The early sustained recovery group was more likely to have a diagnosis other than schizophrenia, particularly mania or brief psychosis.
"Since the current generation of psychiatrists has been raised on second-generation antipsychotics and has relatively little experience with first-generation antipsychotics, keeping tardive dyskinesia in mind is not, on the whole, part of their experience or training," said Christoph U. Correll, MD.
Although various clinical and psychosocial factors were associated with unhealthy lifestyle factors and higher risk for CVD, the strongest associations were with negative symptoms.
Ketamine-dependent patients who exhibited psychosis demonstrated levels of spatial problem solving and verbal memory impairment similar to those of patients with schizophrenia.
Treatment beyond antipsychotic drugs is needed for people with schizophrenia, as positive symptoms are a peripheral node in the network.
Despite the recognition that early daily tobacco use likely increases the risk for later psychosis, investigation of the effect of covariates such as substance use, existing psychotic features, or parental/family factors was lacking in the literature.
These results suggest that CBT alone may be insufficient in enhancing work outcomes in patients with schizophrenia, despite its efficacy in treating other symptoms.
The meta-analysis showed raloxifene to be effective for positive symptoms, negative symptoms, and general psychopathology, with greatly homogeneous results.
The findings of this meta-analysis suggested that both repetitive transcranial magnetic stimulation and transcranial direct current stimulation were significantly more effective at improving negative symptoms than sham stimulation.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Should Physicians Treat Family and Friends? Three Experts Weigh In
- Transference in the Age of #MeToo: What Counts as Harassment From a Patient?
- Dialectical Behavior Therapy Effective in Reducing Suicide Attempts, Self-Harm in Adolescents
- Influence of Psychostimulants on BMI and Height in Youth With ADHD
- Medication Adherence Predictors in Patients With Severe Psychiatric Disorders
- Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy
- ADHD Treatments
- Esketamine Nasal Spray: A New Treatment Possibility for Treatment-Resistant Depression
- Pharmacogenetics in Psychiatry: Promising Developments and Potential Pitfalls
- Substance Abuse and Primary Psychosis: A Closer Look
- Functional Restoration for Chronic Pain and Depression in the Elderly: Pharmacotherapy and Beyond
- Efficacy of Long-Acting Injectable Antipsychotics vs Oral Antipsychotics
- Older Age Associated With Worse Major Depressive Disorder Outcomes
- Preoperative Psychiatric Diagnoses Not Associated With Bariatric Surgery Outcomes
- Medical Clearance of Psych Patients in the ED: Consensus Recommendations